as 05-09-2025 3:36pm EST
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Founded: | 2018 | Country: | Ireland |
Employees: | N/A | City: | N/A |
Market Cap: | 583.1M | IPO Year: | 2021 |
Target Price: | $30.63 | AVG Volume (30 days): | 146.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.79 | EPS Growth: | N/A |
52 Week Low/High: | $6.00 - $20.50 | Next Earning Date: | 05-08-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GHRS Breaking Stock News: Dive into GHRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Zacks
4 days ago
TipRanks
2 months ago
TipRanks
2 months ago
TipRanks
2 months ago
TipRanks
2 months ago
MT Newswires
2 months ago
MT Newswires
2 months ago
The information presented on this page, "GHRS GH Research PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.